Ginkgo Bioworks Holdings, INC 8-K filings

Ginkgo Bioworks announced a 48% revenue decrease in Q2 2026 to $20 million and an increased Adjusted EBITDA loss of $36 million, while also securing new government contracts for autonomous labs.

Ginkgo Bioworks Holdings, Inc. announced the date for its second quarter 2026 financial results presentation and Q&A session.

Ginkgo Bioworks shareholders re-elected the board of directors and ratified the appointment of Deloitte & Touche LLP.

Ginkgo Bioworks announced its first quarter 2026 financial results, reporting $19 million in revenue and a GAAP net loss of $76 million, while also completing the divestiture of its Biosecurity business.

Ginkgo Bioworks Holdings, Inc. has completed the sale of its Biosecurity segment to Tower Biosecurity, Inc., receiving approximately 20% equity in the purchaser.

Ginkgo Bioworks Holdings, Inc. is divesting its Biosecurity segment to Tower Biosecurity, Inc. in exchange for a 20% equity stake in the new entity.

Ginkgo Bioworks announced its Q4 and full year 2025 financial results, revealing a strategic pivot towards autonomous labs and the divestiture of its biosecurity business.

Ginkgo Bioworks Holdings, Inc. announced a leadership transition with Dr. Reshma Shetty stepping down as COO, effective January 1, 2026, to focus on autonomous lab expansion, while Jennifer Wipf and CEO Dr. Jason Kelly assume operational responsibilities.

Ginkgo Bioworks reported a significant 56% decrease in total revenue for Q3 2025, alongside a wider GAAP net loss, while reaffirming its full-year 2025 revenue outlook.

Ginkgo Bioworks Holdings, Inc. announced an at-the-market equity offering of up to $100 million of its Class A common stock through Allen & Company LLC for general corporate purposes.

Ginkgo Bioworks Holdings, Inc. announced preliminary court approval for a settlement resolving stockholder derivative actions, including a $4.125 million insurance payment to the company.

Ginkgo Bioworks reports reduced Q2 2025 net loss and improved Adjusted EBITDA, driven by significant cost savings, despite a slight dip in total revenue.

Ginkgo Bioworks Holdings, Inc. announced that its shareholders approved all proposals at the 2025 annual meeting, including the election of seven directors, the ratification of Deloitte & Touche LLP as its independent auditor, and the advisory approval of executive compensation.

Ginkgo Bioworks announced that CFO Mark Dmytruk will resign on May 30, 2025, and Chief Accounting Officer Steven Coen will assume the role, effective upon Dmytruk's departure.

Ginkgo Bioworks announced a 27% increase in total revenue for Q1 2025, driven by restructuring efforts and growth in biopharma and government sectors, along with an expanded cost savings target of $250 million.

Ginkgo Bioworks reports increased Q4 revenue and progress on restructuring, including improved cash flow and cost savings.

Ginkgo Bioworks saw a 61% increase in total revenue in Q3 2024, primarily due to a one-time non-cash revenue release, while also making progress on cost reductions and strategic partnerships.

Ginkgo Bioworks' warrants are set to be delisted from the NYSE due to low trading prices, while the company's common stock has regained compliance with listing requirements.

Ginkgo Bioworks Holdings, Inc. has implemented a 1-for-40 reverse stock split and amended its certificate of incorporation to remove outdated provisions and allow for officer exculpation.

Ginkgo Bioworks shareholders approved a reverse stock split and other charter updates at a special meeting, with the board subsequently setting the split ratio at 1-for-40.

Ginkgo Bioworks reported a 30% decrease in revenue for Q2 2024, alongside an update on its restructuring plan aimed at achieving Adjusted EBITDA breakeven by the end of 2026.

Ginkgo Bioworks is implementing a restructuring plan that includes a workforce reduction of at least 35% and facility consolidation to reduce operational expenditures.

Ginkgo Bioworks held its 2024 annual meeting, electing nine directors and ratifying Deloitte & Touche LLP as its independent auditor.

Ginkgo Bioworks has received a notice from the NYSE for non-compliance with listing standards due to its stock price falling below $1, triggering a six-month period to regain compliance.

Ginkgo Bioworks is implementing a restructuring plan, including significant workforce reductions and facility consolidation, to achieve adjusted EBITDA breakeven by the end of 2026, following a 53% revenue decrease in Q1 2024.

Ginkgo Bioworks has appointed Deloitte as its new independent auditor after Ernst & Young declined to stand for re-appointment.

Ginkgo Bioworks announced its fourth quarter and full year 2023 financial results, highlighting growth in cell engineering services but a decline in overall revenue due to the transition of its biosecurity business.